Akebia Therapeutics (AKBA) Competitors $3.03 +0.05 (+1.68%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$3.10 +0.07 (+2.31%) As of 10/24/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKBA vs. IMVT, XENE, CGON, RARE, AAPG, AMRX, ZLAB, BEAM, CNTA, and IRONShould you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Immunovant (IMVT), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Amneal Pharmaceuticals (AMRX), Zai Lab (ZLAB), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Akebia Therapeutics vs. Its Competitors Immunovant Xenon Pharmaceuticals CG Oncology Ultragenyx Pharmaceutical Ascentage Pharma Group International Amneal Pharmaceuticals Zai Lab Beam Therapeutics Centessa Pharmaceuticals Disc Medicine Akebia Therapeutics (NASDAQ:AKBA) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations. Do institutionals and insiders hold more shares of AKBA or IMVT? 33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 3.0% of Akebia Therapeutics shares are held by company insiders. Comparatively, 1.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate AKBA or IMVT? Akebia Therapeutics presently has a consensus price target of $6.75, suggesting a potential upside of 122.77%. Immunovant has a consensus price target of $28.78, suggesting a potential upside of 51.94%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Akebia Therapeutics is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71Immunovant 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.58 Is AKBA or IMVT more profitable? Immunovant has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -17.91%. Akebia Therapeutics' return on equity of 0.00% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-17.91% N/A -13.47% Immunovant N/A -80.99%-72.23% Which has higher valuation & earnings, AKBA or IMVT? Akebia Therapeutics has higher revenue and earnings than Immunovant. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$203.73M3.94-$69.41M-$0.17-17.82ImmunovantN/AN/A-$413.84M-$2.85-6.65 Does the media prefer AKBA or IMVT? In the previous week, Akebia Therapeutics had 3 more articles in the media than Immunovant. MarketBeat recorded 8 mentions for Akebia Therapeutics and 5 mentions for Immunovant. Akebia Therapeutics' average media sentiment score of 0.69 beat Immunovant's score of 0.60 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, AKBA or IMVT? Akebia Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. SummaryAkebia Therapeutics beats Immunovant on 11 of the 15 factors compared between the two stocks. Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKBA vs. The Competition Export to ExcelMetricAkebia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$790.13M$3.02B$6.24B$10.69BDividend YieldN/A57.75%5.72%4.82%P/E Ratio-17.8227.5331.2830.77Price / Sales3.94613.00563.45174.94Price / CashN/A168.3237.0861.44Price / Book-13.175.6512.056.61Net Income-$69.41M$33.06M$3.33B$277.10M7 Day Performance3.41%3.16%1.93%2.56%1 Month Performance11.81%8.14%7.77%3.77%1 Year Performance90.57%-2.49%56.40%33.01% Akebia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKBAAkebia Therapeutics3.5136 of 5 stars$3.03+1.7%$6.75+122.8%+91.8%$790.13M$203.73M-17.82430Analyst ForecastIMVTImmunovant1.977 of 5 stars$19.22+9.8%$28.78+49.7%-37.9%$3.35BN/A-6.74120News CoverageXENEXenon Pharmaceuticals2.5086 of 5 stars$43.44+4.3%$53.67+23.5%-2.6%$3.35B$9.43M-12.24210CGONCG Oncology2.1026 of 5 stars$43.59+5.1%$58.82+34.9%+19.8%$3.32B$1.14M-24.6361Analyst ForecastRAREUltragenyx Pharmaceutical4.3755 of 5 stars$34.40+5.4%$81.50+136.9%-38.8%$3.32B$560.23M-6.221,294News CoverageAnalyst ForecastGap UpAAPGAscentage Pharma Group InternationalN/A$35.31-0.4%N/AN/A$3.29B$390.60M0.00600Positive NewsAMRXAmneal Pharmaceuticals2.3952 of 5 stars$10.24+3.2%$12.00+17.2%+27.0%$3.22B$2.79B1,025.038,100Analyst ForecastZLABZai Lab2.7341 of 5 stars$28.74+1.6%$56.35+96.1%-20.7%$3.21B$398.99M-14.091,869News CoverageAnalyst ForecastAnalyst RevisionBEAMBeam Therapeutics3.6132 of 5 stars$30.62+17.9%$45.92+50.0%+26.6%$3.10B$63.52M-6.80510News CoverageAnalyst ForecastHigh Trading VolumeCNTACentessa Pharmaceuticals3.4951 of 5 stars$22.79-1.0%$32.38+42.1%+55.8%$3.05B$15M-12.73200News CoverageAnalyst ForecastIRONDisc Medicine2.8426 of 5 stars$87.17-3.1%$108.73+24.7%+86.2%$3.03BN/A-19.5030Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies IMVT Alternatives XENE Alternatives CGON Alternatives RARE Alternatives AAPG Alternatives AMRX Alternatives ZLAB Alternatives BEAM Alternatives CNTA Alternatives IRON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKBA) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKBA Stock Alerts